Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.53 USD | +4.06% | -5.40% | +176.43% |
05-10 | Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating | MT |
05-09 | Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+176.43% | 2.24B | |
+25.82% | 49.18B | |
+0.90% | 42.11B | |
+50.18% | 40.37B | |
-5.26% | 28.85B | |
+12.83% | 26.09B | |
-22.19% | 18.71B | |
+8.31% | 13.26B | |
+31.94% | 12.32B | |
+0.08% | 11.99B |
- Stock Market
- Equities
- VERA Stock
- News Vera Therapeutics, Inc.
- Oppenheimer Raises Vera Therapeutics Price Target to $34 From $26, Maintains Outperform Rating